[go: up one dir, main page]

NO20080697L - Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor - Google Patents

Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor

Info

Publication number
NO20080697L
NO20080697L NO20080697A NO20080697A NO20080697L NO 20080697 L NO20080697 L NO 20080697L NO 20080697 A NO20080697 A NO 20080697A NO 20080697 A NO20080697 A NO 20080697A NO 20080697 L NO20080697 L NO 20080697L
Authority
NO
Norway
Prior art keywords
enzyme inhibitor
cyclooxygenase enzyme
release
dosage forms
sodium lauryl
Prior art date
Application number
NO20080697A
Other languages
English (en)
Norwegian (no)
Inventor
Rajesh Jain
Chand Kour Jindal
Sukhjeet Singh
Munish Talwar
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of NO20080697L publication Critical patent/NO20080697L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20080697A 2005-07-20 2008-02-07 Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor NO20080697L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1899DE2005 2005-07-20
PCT/IN2006/000258 WO2007010559A2 (en) 2005-07-20 2006-07-19 Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor

Publications (1)

Publication Number Publication Date
NO20080697L true NO20080697L (no) 2008-04-18

Family

ID=37669241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080697A NO20080697L (no) 2005-07-20 2008-02-07 Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor

Country Status (20)

Country Link
US (1) US20100204333A1 (ru)
EP (1) EP1906933A2 (ru)
JP (1) JP2009501785A (ru)
KR (1) KR20080032209A (ru)
CN (1) CN101227893A (ru)
AR (1) AR055090A1 (ru)
AU (1) AU2006271150A1 (ru)
BR (1) BRPI0613547A2 (ru)
CA (1) CA2614850A1 (ru)
CR (1) CR9828A (ru)
DE (1) DE202006020331U1 (ru)
DK (1) DK200900115U1 (ru)
EA (1) EA200800370A1 (ru)
MX (1) MX2008000967A (ru)
NO (1) NO20080697L (ru)
RS (1) RS20080020A (ru)
TN (1) TNSN08018A1 (ru)
UA (1) UA89684C2 (ru)
WO (1) WO2007010559A2 (ru)
ZA (1) ZA200801592B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090007608A (ko) * 2006-04-24 2009-01-19 파나세아 바이오테크 리미티드 니메술리드를 포함하는 새로운 형태의 저복용 약학조성물 및 이의 조제 및 사용방법
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
US8546450B1 (en) * 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
CN102188386B (zh) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 尼美舒利缓释微丸及其制备方法
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
MX2014008283A (es) * 2012-01-04 2015-03-03 Wellesley Pharmaceutical Llc Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
US20130203781A1 (en) 2012-02-06 2013-08-08 William L. Pridgen Aciclovir and celecoxib combination therapy for functional somatic syndromes
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
JP2001515854A (ja) * 1997-09-11 2001-09-25 ニュコメデ ダンマルク アクティーゼルスカブ 非ステロイド性抗炎症薬物質（ＮＳＡＩＤｓ）の改良された開放性多重−単位組成物
IN188720B (ru) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU718356B2 (en) * 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
TR200100708T2 (tr) 1998-09-10 2001-07-23 Nycomed Danmark A/S İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
IN190018B (ru) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
JP4359412B2 (ja) * 1999-09-28 2009-11-04 パナセア バイオテック リミテッド ニメスリドを含む制御放出組成物
US20020015735A1 (en) * 1999-12-22 2002-02-07 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1272181A2 (en) 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
IN190963B (ru) * 2000-06-20 2003-09-06 Ajanta Pharma Ltd
AU2003272601B2 (en) 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
ATE366105T1 (de) * 2003-03-03 2007-07-15 Sprl Franpharma Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone

Also Published As

Publication number Publication date
EP1906933A2 (en) 2008-04-09
DE202006020331U1 (de) 2008-09-18
US20100204333A1 (en) 2010-08-12
BRPI0613547A2 (pt) 2011-01-18
WO2007010559A3 (en) 2007-09-20
CN101227893A (zh) 2008-07-23
EA200800370A1 (ru) 2008-06-30
MX2008000967A (es) 2008-03-26
DK200900115U1 (en) 2009-10-23
AR055090A1 (es) 2007-08-08
ZA200801592B (en) 2009-10-28
TNSN08018A1 (en) 2009-07-14
CA2614850A1 (en) 2007-01-25
UA89684C2 (ru) 2010-02-25
RS20080020A (sr) 2009-05-06
CR9828A (es) 2008-07-31
JP2009501785A (ja) 2009-01-22
KR20080032209A (ko) 2008-04-14
WO2007010559A2 (en) 2007-01-25
AU2006271150A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MXPA05006194A (es) Metodo para utilizar una composicion de bebida.
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
NO20074628L (no) Formuleringer av octreotid med kontrollert frigjoring
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20070445L (no) Pyrimidinderivater.
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
MX2024001581A (es) Derivados de ribosa modificados con 1'-alquilo y metodos de uso.
BRPI0507834A (pt) método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
ZA202212095B (en) Il4i1 inhibitors and methods of use
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
NO20081785L (no) 3-(2-dimetylaminometylcykloheksyl)fenol hemmende formulering
SI1750703T1 (sl) Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
WO2004045380A3 (en) Compositions containing an active fraction isolated from tannins and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application